EMERGENT BIOSOLUTIONS INC. Operating Lease Liability
EMERGENT BIOSOLUTIONS INC. (EBS) had Operating Lease Liability of $6.40 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-06
- 2026-06-30: Operating Lease, Liability $6.40M.
- 2026-03-31: Operating Lease, Liability $11.00M.
- 2025-12-31: Operating Lease, Liability $11.60M.
- 2025-09-30: Operating Lease, Liability $7.90M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $6.40M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $11.00M 10-Q · filed 2026-05-01 |
| 2025-12-31 | $11.60M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $7.90M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $8.30M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $7.00M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $12.40M 10-K · filed 2026-02-27 |
| 2024-09-30 | $13.40M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $14.60M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $16.30M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $17.30M 10-K · filed 2025-03-04 |
| 2023-09-30 | $18.10M 10-Q · filed 2023-12-11 |
| 2023-06-30 | $16.70M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $16.40M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $20.60M 10-K · filed 2024-03-08 |
| 2022-09-30 | $21.50M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $26.80M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $28.40M 10-Q · filed 2022-04-29 |
| 2021-12-31 | $30.00M 10-K/A · filed 2023-12-11 |
| 2021-09-30 | $30.20M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $31.60M 10-Q · filed 2021-07-30 |
| 2021-03-31 | $31.60M 10-Q · filed 2021-04-30 |
| 2020-12-31 | $33.20M 10-K · filed 2022-02-25 |
| 2020-09-30 | $25.10M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $26.10M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $26.90M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $25.70M 10-K · filed 2021-02-19 |
| 2019-09-30 | $19.90M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $16.50M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $13.60M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |